

# Advances in Fertility Preservation and Emerging Therapies for Premature Ovarian Insufficiency: A Comprehensive Review

Aqsa Akram\*

Department of Obstetrics & Gynaecology, Fatima Memorial Hospital, Lahore, Pakistan

## \*Corresponding Author

Department of Obstetrics & Gynaecology, Fatima Memorial Hospital, Lahore, Pakistan.

Submitted: 2025, Dec 01; Accepted: 2025, Dec 23; Published: 2025, Dec 31

**Citation:** Akram, A. (2025). Advances in Fertility Preservation and Emerging Therapies for Premature Ovarian Insufficiency: A Comprehensive Review. *Int Internal Med J*, 3(6), 01-03.

## Abstract

**Background:** Premature ovarian insufficiency (POI) is a distressing reproductive disorder characterized by amenorrhea, estrogen deficiency, and loss of ovarian function before the age of 40. Beyond infertility, POI carries significant long-term consequences related to bone health, cardiovascular disease, and psychological well-being. While fertility options for these women have historically been limited, recent advancements in reproductive medicine have opened new possibilities for fertility preservation and potential restoration of ovarian activity.

**Objective:** This review aims to summarize current fertility preservation strategies, outline emerging therapies showing promise for the future, and evaluate the evidence supporting their clinical utility in women with POI.

**Methods:** A narrative review of relevant literature from PubMed, Google Scholar, and Scopus was conducted. Emphasis was placed on current fertility preservation techniques, experimental interventions, and evolving therapeutic modalities.

**Results:** Established fertility preservation approaches, such as oocyte and embryo cryopreservation, remain the most reliable options for women at risk of POI. Ovarian tissue cryopreservation has emerged as a viable technique, particularly for pre-pubertal girls or those unable to undergo ovarian stimulation. Novel approaches—including ovarian platelet-rich plasma (PRP) therapy, stem cell-based interventions, and in-vitro activation of dormant follicles—have demonstrated encouraging preliminary results, though evidence remains limited and largely experimental.

**Conclusion:** Fertility preservation in POI has evolved significantly over the past decade. While cryopreservation remains the cornerstone of clinical practice, innovative biological therapies offer new hope for restoring fertility. Larger clinical studies are needed to establish safety, efficacy, and long-term outcomes of these emerging techniques.

**Keywords:** Premature Ovarian Insufficiency, Fertility Preservation, Ovarian Tissue Cryopreservation, Stem Cell Therapy, PRP, In-Vitro Activation

## 1. Introduction

Premature ovarian insufficiency (POI), formerly termed premature ovarian failure, affects approximately 1% of women under the age of 40. It is characterized by menstrual irregularity, elevated gonadotropins, and diminished ovarian reserve. The diagnosis

carries profound implications, not only for fertility but also for endocrine, cardiovascular, skeletal, and psychological health.

For many women, infertility is the most devastating aspect of POI. Traditionally, donor oocyte in vitro fertilization (IVF) has

---

been the most effective treatment option, but it does not address the patient's desire for genetic parenthood. Over the last decade, reproductive medicine has increasingly shifted toward strategies that aim to preserve or restore natural fertility in women at risk of POI, particularly those undergoing gonadotoxic treatments or identified with declining ovarian reserve.

With the development of cryobiology, tissue engineering, regenerative medicine, and ovarian rejuvenation techniques, new possibilities have emerged. This review provides a comprehensive overview of established and evolving approaches to fertility preservation in POI, highlighting their clinical applications, limitations, and future directions.

## 2. Methods

A broad narrative review was conducted using available literature published in English. Databases including PubMed, Scopus, and Google Scholar were searched using keywords "premature ovarian insufficiency," "fertility preservation," "ovarian tissue cryopreservation," "stem cell therapy," "PRP," and "in-vitro activation." Preference was given to peer-reviewed articles, clinical studies, systematic reviews, and authoritative guidelines from reproductive medicine societies. The purpose was to provide a balanced, clinically relevant synthesis rather than an exhaustive systematic review.

### 2.1. Pathophysiology of POI (Brief Overview)

The etiological spectrum of POI includes genetic abnormalities, autoimmune conditions, iatrogenic ovarian injury, infections, and idiopathic factors. Regardless of the cause, the central pathological feature is the depletion or dysfunction of ovarian follicles. This underpins the rationale for early fertility preservation and exploration of regenerative therapies aimed at activating or replenishing the follicular pool.

### 2.2. Established Fertility Preservation Options

#### 2.2.1 Oocyte Cryopreservation

Oocyte freezing is widely accepted as the most reliable method for fertility preservation in women with an intact ovarian function. It requires controlled ovarian stimulation followed by oocyte retrieval. While effective, it may not be feasible for women who present late with severely diminished ovarian reserve or those who cannot delay treatment, such as cancer patients.

#### 2.2.2 Embryo Cryopreservation

The technique offers higher success rates than oocyte cryopreservation due to the greater developmental stability of embryos. However, it requires a committed partner or sperm donor, and may not suit unmarried women who prefer future autonomy over reproductive decisions.

#### 2.2.3 Ovarian Tissue Cryopreservation (OTC)

OTC has gained increasing acceptance, particularly for young girls and women unwilling or unable to undergo hormonal stimulation. The procedure involves laparoscopic removal of ovarian cortical tissue, which is then cryopreserved for later transplantation.

### Advantages:

- Suitable for pre-pubertal girls
- Does not require ovarian stimulation
- Offers potential restoration of endocrine as well as reproductive function

More than 200 live births have been reported worldwide from reimplanted ovarian tissue, making it an important tool for women at risk of POI.

## 2.3. Emerging and Experimental Therapies

### 2.3.1 Platelet-Rich Plasma (PRP) Ovarian Rejuvenation

Intra-ovarian PRP injection has gained widespread attention due to its minimally invasive nature. PRP contains growth factors thought to support angiogenesis and follicular activation. Preliminary studies report improvements in hormonal profiles, AMH levels, and occasional spontaneous pregnancies. However, the evidence is inconsistent, and the mechanism remains controversial.

### 2.3.2 Stem Cell Therapy

Stem cell-based interventions aim to regenerate ovarian tissue or support folliculogenesis. Various stem cell types—mesenchymal stem cells, bone marrow-derived stem cells, and adipose-derived stem cells—have been explored.

### Potential Benefits:

- Restoration of hormone production
- Improvement in vascularization of ovarian stroma
- Possible activation of dormant follicles

While animal studies show promising outcomes, human data remain limited to small pilot studies.

## 3. In-Vitro Activation (IVA) of Dormant Follicles

IVA is a sophisticated technique in which ovarian tissue is removed, treated ex vivo with activation signals, and transplanted back into the patient. This approach seeks to activate the remaining primordial follicles. A few live births have been reported, suggesting that IVA may offer a viable possibility for genetically related offspring in selected women with POI.

## 4. Artificial Ovary and Tissue Engineering (Future Direction)

The artificial ovary concept aims to combine isolated follicles with a biocompatible scaffold to create a functional ovarian construct. Although still experimental, it holds potential for women with POI—particularly those with autoimmune or genetic causes where tissue transplantation carries risks.

## 5. Discussion

The landscape of fertility preservation in POI is rapidly evolving. Established methods such as oocyte and tissue cryopreservation have made it possible for women to delay childbearing or preserve their reproductive potential before ovarian decline. While these methods remain the cornerstone of clinical practice, emerging biological and regenerative approaches offer opportunities for women previously considered without options.

However, these new techniques require careful evaluation. Many are supported by limited data, involve experimental protocols, or are offered in private settings without regulatory oversight. As interest grows, clinicians must provide balanced counselling that incorporates realistic expectations and ethical considerations.

### 5.1. Clinical Implications

- Early identification of women at risk of POI is crucial.
- Fertility preservation should be discussed at the time of diagnosis or before potential gonadotoxic exposure.
- Experimental treatments should be offered within controlled clinical research settings.
- Collaborative care between gynecologists, reproductive endocrinologists, and psychologists is essential to support patients emotionally and medically.

### 6. Conclusion

Fertility preservation for women with POI has transitioned from a narrow set of options to a diverse and rapidly developing field. Established cryopreservation methods offer reliable outcomes, while emerging therapies—such as PRP, stem cells, and in-vitro activation—hold significant promise but require further validation. Continued research, ethical vigilance, and patient-centered care are essential to translating these innovations into safe, effective treatments.

### Consent to Participate

This study was all methods were performed in accordance with the relevant guidelines and regulations. Informed written consent was obtained from all individual participants included in the study.

### Acknowledgements

The author would like to acknowledge the staff and administration of the Department of Obstetrics & Gynaecology at Fatima Memorial Hospital, Lahore, for their support and cooperation throughout the duration of this study.

### Authors' Contributions

Dr. Aqsa Akram is the sole author of this manuscript. The author conceived and designed the study, collected and analyzed the data, interpreted the results, and wrote, reviewed, and approved the final manuscript.

### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The work was supported solely by the departmental and institutional resources of Fatima Memorial Hospital, Lahore.

### Competing Interests / Conflict of Interest Disclosure

The author declare no **conflicts of interest** regarding the publication of this article.

### Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

### Consent for Publication

Individual patient data and images are not contained in this manuscript. However, as the study involved the collection and analysis of clinical data from patient medical records, informed consent for the publication of the study's aggregated and anonymized results was obtained from all participating women as part of the written consent process for participation in the research.

### References

1. Nelson, L. M. (2009). Primary ovarian insufficiency. *New England Journal of Medicine*, 360(6), 606-614.
2. Donnez J, Dolmans MM. Ovarian tissue cryopreservation and transplantation: fertility restoration and beyond. *J Clin Endocrinol Metab*. 2013;98(10):3931–3941.
3. Kawamura, K., Ishizuka, B., & Hsueh, A. J. (2020). Drug-free in-vitro activation of follicles for infertility treatment in poor ovarian response patients with decreased ovarian reserve. *Reproductive biomedicine online*, 40(2), 245-253.
4. Cakiroglu Y, Yuceturk A, Kara M, et al. Ovarian reserve and menstrual pattern after ovarian PRP treatment. *Reprod Sci*. 2020;27(8):1664–1673.
5. De Vos M, Smits J, Woodruff TK. Fertility preservation in women with diminished ovarian reserve or primary ovarian insufficiency. *Clin Obstet Gynecol*. 2010;53(4):755–762.
6. De Vos, M., Devroey, P., & Fauser, B. C. (2010). Primary ovarian insufficiency. *The Lancet*, 376(9744), 911-921.
7. Anderson, R. A., & Wallace, W. H. B. (2011). Fertility preservation in girls and young women. *Clinical endocrinology*, 75(4), 409-419.
8. Labarta E, de Los Santos MJ, Escribá MJ, et al. Autologous platelet-rich plasma (PRP) in assisted reproduction: a pilot study. *Reprod Biomed Online*. 2019;38(3):397–405.
9. Abir R, Ben-Haroush A, Felz C, et al. Transplantation of cryopreserved ovarian tissue: a systematic review. *Hum Reprod Update*. 2012;18(5):540–557.
10. Ding C, Zou Q, Wang F, et al. Mesenchymal stem cell therapy for premature ovarian insufficiency: a systematic review and meta-analysis. *Stem Cell Res Ther*. 2020;11:161.

**Copyright:** ©2025 Aqsa Akram. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.